Full-service CRO, spun from Labcorp. Turnaround story — lower margin, smaller scale than IQV/ICLR/MEDP. Higher risk, higher potential upside.
Conviction●○○○○1 of 5
Research target—Snapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap1.63BSnapshot value
Turnaround execution under independent management; biotech funding recovery; FSP model adoption; potential M&A target in consolidating CRO market.
Turnaround execution risk; smaller scale creates competitive disadvantage vs IQV/ICLR; margin pressure; Labcorp spin-off overhang.
needs X/Reddit sentiment sweep
Snapshot · Not reviewed🟢 Lean-Bull · ins-$0.4M · 13F 19+/6- · short↑0.22
Snapshot · Not reviewed